Scotch Plains, NJ, United States of America

Eric J Gilbert

USPTO Granted Patents = 27 (Patent Applications = 4)

CIPO Patents = 1

EPO Patents = 14 (Patent Applications = 13)

Average Co-Inventor Count = 6.3

ph-index = 10

Forward Citations = 278(Granted Patents)

Company Filing History:

18 out of 2,405

Merck Sharp + Dohme Corp.

Ra Pharmaceuticals, Inc.

Intervet International B.v.

patents

where one patent can have more than one assignee

Years Active: 2002-2024

Loading Chart...

27 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 12012468 - Cyclic polypeptides for PCSK9 inhibition (2024-06-18),

2. 11530244 - Cyclic polypeptides for PCSK9 inhibition (2022-12-20),

3. 11161819 - Substituted tetrahydroisoquinoline compounds useful as GPR120 agonists (2021-11-02),

4. 9687494 - Iminothiadiazine dioxide compounds as BACE inhibitors, compositions, and their use (2017-06-27),

5. 9499502 - 5-substituted iminothiazines and their mono- and dioxides as BACE inhibitors, compositions, and their use (2016-11-22),

6. 9475785 - Iminothiadiazine dioxide compounds as BACE inhibitors, compositions and their use (2016-10-25),

7. 9453034 - C2-azaspiro iminothiazine dioxides as BACE inhibitors, compositions, and their use (2016-09-27),

8. 9428475 - Iminothiadiazine dioxide compounds as BACE inhibitors, compositions, and their use (2016-08-30),

9. 9422277 - Tricyclic substituted thiadiazine dioxide compounds as BACE inhibitors, compositions and their use (2016-08-23),

10. 9416129 - Tricyclic substituted thiadiazine dioxide compounds as BACE inhibitors, compositions and their use (2016-08-16),

11. 9221839 - C5-C6 oxacyclic-fused thiadiazine dioxide compounds as BACE inhibitors, compositions, and their use (2015-12-29),

12. 9145426 - Pyrrolidine-fused thiadiazine dioxide compounds as BACE inhibitors, compositions, and their use (2015-09-29),

13. 9029362 - Iminothiadiazine dioxide compounds as brace inhibitors, compositions, and their use (2015-05-12),

14. 8940748 - Iminothiadiazine dioxide compounds as BACE inhibitors, compositions, and their use (2015-01-27),

15. 8735604 - Pyrrolidines as glucagon receptor antagonists, compositions, and methods for their use (2014-05-27),

Title: Eric J Gilbert: A Pioneer in PCSK9 Inhibition

Introduction

Eric J Gilbert, based in Scotch Plains, NJ, is an accomplished inventor with a remarkable portfolio of 27 patents. His innovative work focuses primarily on cyclic polypeptides that play a significant role in cholesterol metabolism, particularly in the inhibition of PCSK9, a key protein involved in cholesterol regulation.

Latest Patents

Among his latest inventions, Gilbert has developed cyclic polypeptides specifically designed for PCSK9 inhibition. These compounds are notable for their ability to bind selectively to human PCSK9 and inhibit its interaction with the low-density lipoprotein receptor (LDLR). This innovation opens avenues for pharmaceutical compositions aimed at reducing LDL cholesterol levels in patients, thus contributing to advancements in cardiovascular health.

Career Highlights

Throughout his career, Eric J Gilbert has made significant contributions to the pharmaceutical field, particularly through his tenure at reputable companies such as Merck Sharp & Dohme Corporation and Schering Corporation. His work has significantly enhanced the understanding and treatment options available for conditions related to high cholesterol levels.

Collaborations

Gilbert has collaborated with notable professionals in the industry, including Andrew William Stamford and Jack D Scott. These partnerships have likely enriched his research endeavors and propelled his contributions to the field of pharmacology.

Conclusion

Eric J Gilbert stands out as an inventor whose work has profound implications for health care and cardiovascular treatments. His dedication to innovation in pharmaceuticals through his patented cyclic polypeptides marks him as a key figure in the ongoing battle against high cholesterol, making a substantial impact in the medical community.

This text is generated by artificial intelligence and may not be accurate.